All News

The international treaty on plant genetic resources needs a gesture of trust to repair the atmosphere of suspicion that has developed, argues Emile Frison from the International Plant Genetic Resources Institute.

USA Today reports declining R&D budgets in the USA, albeit in, it seems, just one tech sector.

The EU wants 25 per cent of transport energy will come from biofuels by the year 2030 – and is backing research that it will help it get there.

A team of researchers from ETH-Zürich is looking for investment for their spin-off company, XpresSys, to commercialise novel protein expression technology. The technology has the potential to revolutionise screening process for new drugs.

It may have started from a low base, but the Indian biotech industry is hurtling past the global growth rate. And overseas companies are anxious to get in on the action.

For a bunch of IT experts, the EU's IST World has come up with a baffling web site, especially when the idea is to make life easy for beginners.

Indian firms are training large numbers of patent agents - with their eye on the large number of companies abroad looking for cheaper patenting.

Cuts in federal funding have forced UC Berkeley's RAD Lab to seek industry funding. But the money may not be enough to plug the gap.

Biology Information Open Source's promoter, Richard Jefferson, asserts that BIOS is explicitly modelled after the Open Source initiative in software. But science is grounded in open exchange and the sharing of information, so what is the point of BIOS and other initiatives such as Science Commons?

Software agents could change the way that computing works. You just leave them to get on with the work.

Universities in Ireland can now bid for funds to beef up their knowledge transfer activities.

Every business has to issue a press release one day. When they do so, they should remember that jargon does not help get the message across.

In an earlier blog, I deplored the lack of data about the European IP market and in particular about the academic licensing business. I am delighted to report that my “bottle in the ocean” approach has produced results.

The TeGenero drug trial is complete, and an ongoing study is examing whether trial requirements should be changed. But, asks Nuala Moran, should the trial ever have been approved?

Active Solar Buildings – entirely heated and cooled by solar thermal energy – should become the standard by 2030 if the vision of the EU’s latest Technology Platform is realised.